This episode is a collaboration between the ACCP Ambulatory Care Practice and Research Network (PRN) ... and iForumRx.org.

The treatment of dyslipidemia has gotten a lot more complex in recent years as we now have several non-statins that can substantially lower LDL cholesterol and reduce cardiovascular event rates - including PCSK9 monoclonal antibodies, ezetimibe, bempedoic acid, and inclisiran. When and how should we be using these agents?

Panelists:  David Dixon, PharmD, BCACP, CDCES, CLS; Kathryn Litten, PharmD, BCACP; and Tomasz Jurga, PharmD, BCPS, BCACP, BCCP, CDCES

Produced by Jonathan Hughes, PharmD, BCPS, BCACP and Anna Love, PharmD, BCACP

Music by lemonmusicstudio from Pixabay